CD4+ T Cells: Multitasking Cells in the Duty of Cancer Immunotherapy.
CD4+ T Cells: Multitasking Cells in the Duty of Cancer Immunotherapy.
复制标题
DOI：
10.3390/cancers13040596
复制
发表时间：
2021-02-03
期刊：
影响因子：
5.2
通讯作者：
Schuhmacher J
中科院分区：
文献类型：
--
作者：
Richardson JR;Schöllhorn A;Gouttefangeas C;Schuhmacher J
在其细胞表面上携带共受体CD 4的T细胞是发挥促炎或抗炎功能的T淋巴细胞的异质组。来自小鼠模型和癌症患者的证据表明，各种CD 4 + T细胞亚群在抗肿瘤免疫应答中起拮抗作用。本文综述了目前对CD 4 + T细胞亚群的了解，它们如何影响患者的肿瘤生长，以及这些细胞在最新的癌症免疫治疗中发挥的作用。癌症免疫疗法激活免疫系统以特异性靶向恶性细胞。研究通常集中在CD 8+细胞毒性T细胞上，因为这些细胞在TCR-MHC I类相互作用后特异性识别后具有消除肿瘤细胞的能力。然而，CD 4 + T细胞在本领域中已经获得关注，因为它们不仅对促进CD 8 + T细胞的辅助是必需的，而且还能够直接（通过MHC II类依赖性识别）或间接（例如，通过激活其它免疫细胞如巨噬细胞）。因此，免疫治疗方法已经从仅刺激CD 8 + T细胞转变为靶向和评估CD 4+和CD 8 + T细胞亚群。在这里，我们讨论了CD 4 + T细胞的各种亚群，它们的可塑性和功能，它们在受癌症影响的患者的抗肿瘤免疫反应中的相关性，以及它们在人类癌症治疗方法中日益增长的作用。
T cells bearing the co-receptor CD4 on their cell surface are a heterogeneous group of T lymphocytes that exert pro- or anti-inflammatory functions. Evidence from mouse models and cancer patients reveal that various CD4+ T cell subsets play an antagonistic role in the antitumor immune response. This review summarizes current knowledge on CD4+ T cell subsets, on how they impact tumor growth in patients, and which role these cells play in newest cancer immunotherapies. Cancer immunotherapy activates the immune system to specifically target malignant cells. Research has often focused on CD8+ cytotoxic T cells, as those have the capacity to eliminate tumor cells after specific recognition upon TCR-MHC class I interaction. However, CD4+ T cells have gained attention in the field, as they are not only essential to promote help to CD8+ T cells, but are also able to kill tumor cells directly (via MHC-class II dependent recognition) or indirectly (e.g., via the activation of other immune cells like macrophages). Therefore, immunotherapy approaches have shifted from only stimulating CD8+ T cells to targeting and assessing both, CD4+ and CD8+ T cell subsets. Here, we discuss the various subsets of CD4+ T cells, their plasticity and functionality, their relevance in the antitumor immune response in patients affected by cancer, and their ever-growing role in therapeutic approaches for human cancer.
登录
查看更多内容
影响因子：
82.9
作者：
Gattinoni L;Speiser DE;Lichterfeld M;Bonini C
通讯作者：
Bonini C
影响因子：
82.9
作者：
Gattinoni L;Lugli E;Ji Y;Pos Z;Paulos CM;Quigley MF;Almeida JR;Gostick E;Yu Z;Carpenito C;Wang E;Douek DC;Price DA;June CH;Marincola FM;Roederer M;Restifo NP
通讯作者：
Restifo NP
影响因子：
64.8
作者：
Cabrita, Rita;Lauss, Martin;Jonsson, Goran
通讯作者：
Jonsson, Goran
影响因子：
11.5
作者：
Giraldo, Nicolas A.;Becht, Etienne;Sautes-Fridman, Catherine
通讯作者：
Sautes-Fridman, Catherine
DOI：
10.1084/jem.20101876
发表时间：
2011-03-14
期刊：
The Journal of experimental medicine
影响因子：
--
作者：
De Monte L;Reni M;Tassi E;Clavenna D;Papa I;Recalde H;Braga M;Di Carlo V;Doglioni C;Protti MP
通讯作者：
Protti MP